Get the Stockscreener App
33.98
0.97%
0.3604
Immunovant Inc stock is traded at $33.98, with a volume of 409.74K.
It is up +0.97% in the last 24 hours and up +23.49% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
See More
Previous Close:
$33.62
Open:
$34.02
24h Volume:
409.74K
Relative Volume:
0.23
Market Cap:
$6.98B
Revenue:
-
Net Income/Loss:
$-505.61M
P/E Ratio:
-12.27
EPS:
-2.7697
Net Cash Flow:
$-407.32M
1W Performance:
+10.22%
1M Performance:
+23.49%
6M Performance:
+30.56%
1Y Performance:
+116.77%
1-Day Range:
$33.56
$34.21
1-Week Range:
$30.24
$34.21
52-Week Range:
$14.32
$36.28
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-410-3120
Address
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
33.98 | 6.90B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
451.26 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.62 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
882.51 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.00 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.81 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Mkt Perform |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - Yahoo Finance
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant Q4 2026 earnings preview - MSN
Immunovant Inc stock (US45258Q1058): shares trade around mid-30 USD ahead of next catalysts - AD HOC NEWS
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary - Yahoo Finance
Behavioral Patterns of IMVT and Institutional Flows - Stock Traders Daily
IMVT Technical Analysis & Stock Price Forecast - Intellectia AI
Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data - Insider Monkey
13 Best Short Squeeze Stocks to Invest In - Insider Monkey
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options - Stock Titan
Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum - simplywall.st
[144] Immunovant, Inc. SEC Filing - Stock Titan
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating - Insider Monkey
Analysts’ Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT) - The Globe and Mail
J.P. Morgan Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Selling US$2.3m Of Stock Was Lucrative Decision For Immunovant Insiders - 富途牛牛
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers - Barron's
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT) - Seeking Alpha
(IMVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune PivotHas The Bull Case Changed? - simplywall.st
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Immunovant COO Gloria Melanie sells $101,072 in company stock By Investing.com - Investing.com India
Immunovant COO Gloria Melanie sells $101,072 in company stock - Investing.com
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT) - The Globe and Mail
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Sahm
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $43 - Moomoo
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications - TipRanks
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider LossesHas The Bull Case Changed? - Yahoo Finance
Immunovant director Atul Pande sells $192,000 in shares By Investing.com - Investing.com Nigeria
IMVT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IMVT Maintains Buy Rating by B of A Securities -- Price Target R - GuruFocus
IMVT Maintains by HC Wainwright & Co. -- Price Target Raised to $40 - GuruFocus
Immunovant (IMVT) Stock Shot up after a Poor Quarterly Showing - FXLeaders
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $45 - Moomoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - The Globe and Mail
BofA raises Immunovant stock price target on higher peak sales outlook - Investing.com
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fromkin Andrew J. | Director |
May 28 '26 |
Sale |
33.51 |
221,951 |
7,438,111 |
74,382 |
1.35%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):